This invention belongs to the field of
pharmaceutical technology, specifically relating to the application of
psoralen in the preparation of drugs for the prevention and treatment of
rheumatoid arthritis. This invention aims to address the problem of insufficient
efficacy and inadequate clinical needs of existing
rheumatoid arthritis prevention and treatment drugs, filling the technological gap in the pharmacological activity of
psoralen against
rheumatoid arthritis. Studies have confirmed that
psoralen can effectively inhibit the
secretion of IL-6 and IL-8 by RA-FLS cells, effectively inhibit RA-FLS
cell proliferation, migration, and invasion, significantly improve
joint swelling and
weight loss symptoms in CIA mice, effectively regulate immune imbalance, and effectively repair joint
pathological damage. It blocks the
pathological processes of rheumatoid
arthritis, including
inflammation, immune disorders, synovial damage, and bone destruction, from multiple pathways and dimensions. Furthermore, psoralen is a natural
plant-derived component. This invention provides a novel natural
drug option for the treatment of rheumatoid
arthritis, effectively improving the
existing treatment system for the
disease.